Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
JL Chiasson, RG Josse, R Gomis, M Hanefeld… - The Lancet, 2002 - thelancet.com
Background The worldwide increase in type 2 diabetes mellitus is becoming a major health
concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of …
concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of …
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial
JL Chiasson, RG Josse, R Gomis, M Hanefeld… - Jama, 2003 - jamanetwork.com
ContextThe worldwide explosive increase in type 2 diabetes mellitus and its cardiovascular
morbidity are becoming major health concerns.ObjectiveTo evaluate the effect of decreasing …
morbidity are becoming major health concerns.ObjectiveTo evaluate the effect of decreasing …
[PDF][PDF] Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications
…, JP Bantle, CA Beebe, JD Brunzell, JL Chiasson… - Diabetes …, 2002 - researchgate.net
Historically, nutrition principles and recommendations for diabetes and related complications
have been based on scientific evidence and diabetes knowledge when available and, …
have been based on scientific evidence and diabetes knowledge when available and, …
The efficacy of acarbose in the treatment of patients with non–insulin-dependent diabetes mellitus: A multicenter, controlled clinical trial
JL Chiasson, RG Josse, JA Hunt… - Annals of internal …, 1994 - acpjournals.org
Objective: To evaluate the long-term efficacy of acarbose, an α-glucosidase inhibitor, in
improving glycemic control in patients with non–insulin-dependent diabetes mellitus. Design: A 1-…
improving glycemic control in patients with non–insulin-dependent diabetes mellitus. Design: A 1-…
Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state
JL Chiasson, N Aris-Jilwan, R Bélanger, S Bertrand… - Cmaj, 2003 - Can Med Assoc
DIABETIC KETOACIDOSIS AND THE HYPERGLYCEMIC hyperosmolar state are the most
serious complications of diabetic decompensation and remain associated with excess …
serious complications of diabetic decompensation and remain associated with excess …
[HTML][HTML] The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on …
…, AL Gibbs, C Mehling, JL Chiasson… - The American journal of …, 2008 - Elsevier
Background The optimal source and amount of dietary carbohydrate for managing type 2
diabetes (T2DM) are unknown. Objective We aimed to compare the effects of altering the …
diabetes (T2DM) are unknown. Objective We aimed to compare the effects of altering the …
Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal …
…, J Bourque, F Ducros, JL Chiasson - Diabetes …, 2001 - Am Diabetes Assoc
OBJECTIVE—To evaluate and validate appropriate premeal insulin dose reductions for
postprandial exercises of different intensities and durations to minimize the risk of exercise-…
postprandial exercises of different intensities and durations to minimize the risk of exercise-…
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance
M Hanefeld, JL Chiasson, C Koehler, E Henkel… - Stroke, 2004 - Am Heart Assoc
Background and Purpose— Impaired glucose tolerance (IGT)–a prediabetic state–is an
important risk factor for atherosclerosis. Acarbose, an α-glucosidase inhibitor, was shown in the …
important risk factor for atherosclerosis. Acarbose, an α-glucosidase inhibitor, was shown in the …
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double …
…, RL Coleman, JCN Chan, JL Chiasson… - The lancet Diabetes & …, 2017 - thelancet.com
Background The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes
in patients with coronary heart disease and impaired glucose tolerance is unknown. We …
in patients with coronary heart disease and impaired glucose tolerance is unknown. We …
The STOP-NIDDM trial: an international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance …
JL Chiasson, R Gomis, M Hanefeld, RG Josse… - Diabetes …, 1998 - Am Diabetes Assoc
OBJECTIVE To describe the rationale and design, and to discuss the preliminary screening
data, of the Study to Prevent NIDDM (STOP-NIDDM Trial), an international study on the …
data, of the Study to Prevent NIDDM (STOP-NIDDM Trial), an international study on the …
